This is a protocol preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Method Article
Sibaprasad Bhattacharyya
Imaging Probe Development Group
Corresponding Author
License:
This work is licensed under a CC BY-NC 3.0 License. Read Full License
A robust protocol has been developed for producing clinical-grade 89Zr-panitumumab as an immuno-PET probe to evaluate EGFR- targeted therapy. In this protocol, clinical-grade panitumumab is bio-conjugated with desferrioxamine chelate and subsequently radiolabeled with 89Zr resulting in high radiochemical yield (> 70 %, n = 3) and purity (> 98%, n = 3). All quality control (QC) tests were performed according to USP specifications (USP general chapter <823>). QC tests showed that the 89Zr-panitumumab met all specifications for human injection. This protocol describes a step-by-step method for the facile synthesis and quality control tests of 89Zr-panitumumab for medical use. The entire process of bioconjugation, radiolabeling, and all QC tests take about 5 h.
Keywords
89Zr, USP, Immuno-PET, EGFR
Figure 1
none
This is a list of supplementary files associated with this preprint. Click to download.
- supplement0.docx
Table 1 and Table 2 Tables
Loading...
Version History
CURRENT STATUS: Posted
Version 1
Posted 26 Sep, 2013
No community comments so far
Metrics
Comments: 0
HTML Views: ...
Associated Publications
Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas
by Sibaprasad Bhattacharyya, Karen Kurdziel, Ling Wei, +7
Method Article
Sibaprasad Bhattacharyya
Imaging Probe Development Group
Corresponding Author
Version History
CURRENT STATUS: Posted
Version 1
Posted 26 Sep, 2013
No community comments so far
Metrics
Comments: 0
HTML Views: ...
License:
This work is licensed under a CC BY-NC 3.0 License. Read Full License
A robust protocol has been developed for producing clinical-grade 89Zr-panitumumab as an immuno-PET probe to evaluate EGFR- targeted therapy. In this protocol, clinical-grade panitumumab is bio-conjugated with desferrioxamine chelate and subsequently radiolabeled with 89Zr resulting in high radiochemical yield (> 70 %, n = 3) and purity (> 98%, n = 3). All quality control (QC) tests were performed according to USP specifications (USP general chapter <823>). QC tests showed that the 89Zr-panitumumab met all specifications for human injection. This protocol describes a step-by-step method for the facile synthesis and quality control tests of 89Zr-panitumumab for medical use. The entire process of bioconjugation, radiolabeling, and all QC tests take about 5 h.
Figure 1
Loading...
Associated Publications
Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas
by Sibaprasad Bhattacharyya, Karen Kurdziel, Ling Wei, +7